235 East 42nd Street
About Pfizer Inc.
Imagine touching the lives of people everywhere. Imagine reaching beyond the ordinary and impacting something greater than the bottom line. Imagine influencing some of the most critical issues facing healthcare today.
At Pfizer Global Research & Development (PGRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.
To date, PGRD has brought to market a wide range of medicines, such as Lipitor® (atorvastatin calcium), Zithromax® (azithromycin), Viracept® (nelfinavir mesylate), Zoloft® (sertraline hydrochloride), Viagra® (sildenafil citrate), and our newest smoking cessation medicine, Chantix® (varenicline). And, today, with a broad research pipeline that spans many therapeutic areas, we are determined to bring even more cures to the marketplace.
But there is much more work to be done and we can’t do it alone. We’re always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.
Why Join Pfizer?
Pfizer offers the opportunity to work on promising research, access to unparalleled resources and world-class facilities, and the chance to work with some of the brightest and most driven individuals in the pharmaceutical industry.
At Pfizer, we build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues. As an integral member of our team, you'll find myriad opportunities to assert your professional independence as you generate results that will advance our ultimate goal of creating life-enhancing therapies.
In addition to creating the environment for innovation, our values have led to numerous corporate awards acknowledging excellence in many domains - with investors, our business partners, and our employees. We've been praised as “One of the 100 Best Companies for Working Mothers” by Working Mother® Magazine (9/07), honored with “The Best Employers for Healthy Lifestyles 2007 Award” by the National Business Group on Health (5/07), and awarded by the Women's Business Enterprise National Council on its annual listing of America's Top Corporations for Women's Business Enterprises (3/07).
At PGRD, your success is critical to our success. PGRD offers world-class career opportunities, directing resources and time that result in a high-level scientific professional track. Our employees and external rankings with the leading authorities attest to the fact that PGRD is one of the best companies to work for - where you choose a lifestyle - not just a job.
• La Jolla, CA
Located north of downtown San Diego, La Jolla boasts southern California's most beautiful and majestic coastline, with an abundance of cultural, outdoor recreation, and big city activities. Home to Salk Institute and Scripps Research Institute - two renowned academic institutions - and many major biotechnology and telecommunications firms, La Jolla offers a rich environment for both scientists and engineers.
• New London and Groton, CT
Located on the southeastern Connecticut seashore in a historical New England vacation area known for its seafood, easy pace of living, and nautically related recreational activities. It's also within reasonable driving distance to a wealth of greater academic institutions, and within a couple of hours of Boston and New York.
• St. Louis, MO
Known as the Gateway to the West, St. Louis is a diverse, vibrant metropolitan area of 2.5 million, with a broad-based economy. Residents enjoy professional sports teams, a world-class symphony orchestra, botanical gardens, and numerous other outdoor activities. Additionally, scientists have the opportunity to collaborate with researchers at Washington University School of Medicine.
• Sandwich, UK
Sandwich, once a major port in England but now 2 miles from the sea, is one of the best-preserved Medieval towns in the UK, with its old town walls and "Kent Peg" roof houses. Situated close to the city of Canterbury and only 80 miles from London, the area is steeped in history and is ideal for those who enjoy water sports. The rail links across the English Channel also mean that you can be in France within an hour, providing access to the whole of Europe.
At PGRD, we celebrate the talents and diversity of our employees. We respect our employees' lives and provide a multitude of resources and supports to help foster a work/life balance. Also, in addition to our outstanding career opportunities and quality of life, we offer a wide array of topnotch and leading-edge benefits, competitive compensation, and exceptional long-term financial rewards designed to ensure your well-being and financial security. We offer you choices so you can craft a plan that meets your individual and family needs.
Your talent can change the world. Join us.
To learn more about our people, our products, and our plans for the future, visit www.pfizer.jobs
We’re proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds, and ethnic origins.
Founder: Charles Pfizer
CEO: Ian C. Read
CMO: Freda C. Lewis-Hall, M.D., DFAPA
CFO: Frank D’Amelio
Please click here for clinical trial information.
For more information, visit
www.pfizer.com and follow us on www.twitter.com/Pfizer.
Tweets by Pfizer
Innovating for Healthier Lives
3790 articles with Pfizer Inc.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meeting
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2018.
Pfizer announced results from its Phase IIa clinical trial of PF-06651600 and PF-06700841 in alopecia areata (AA).
Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic ...
9/17/2018Following a trial failure with its atopic dermatitis treatment, Malvern, Penn.-based Realm Therapeutics has opted to discontinue all of its drug development programs and is considering a potential sale of the company.
Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Pfizer Inc. today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with profound psychological consequences.
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
Although Hurricane Florence has been downgraded to a Category 2, the massive storm has the potential to dump enough rain to produce catastrophic flooding across the Carolinas. Despite the downgrade, Pfizer is taking no chances and will close its North Carolina injectables plant ahead of the storm.
Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.
Late-stage trial results show that a combination of Bavencio (avelumab) and Inlyta (axitinib) significantly improved progression-free survival in previously untreated patients with advanced renal cell carcinoma.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m. Eastern Daylight Time.
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy
Although there is a general complaint about drug prices, which rocketed into the public domain during the 2016 U.S. presidential election, nothing particularly dramatic has been done about it.
SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata
Phase II data accepted for late-breaker news session at 2018 EADV Congress
Pfizer Inc. today announced the pricing of a debt offering consisting of six tranches of notes
Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate Combination Therapy with CMP-001 and Avelumab
Phase Ib/II trial will evaluate safety, pharmacokinetics, pharmacodynamics, efficacy of the immunotherapy combination in PD-1/PD-L1-Refractory Advanced Squamous Cell Cancer of the Head and Neck